CURAZID FORTE Isoniazid / Pyridoxine Hydrochloride 200mg / 10mg per 5mL Syrup 120mL
RXDRUG-DR-XY25056
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Curazid Forte
Full Details
Dosage Strength
200mg / 10mg / 5ml
Drug Ingredients
- Isoniazid
- Pyridoxine
Drug Packaging
Syrup 120ml
Generic Name
Isoniazid / Pyridoxine Hydrochloride
Dosage Form
Syrup
Registration Number
DR-XY25056
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Primary treatment of pulmonary and extrapulmonary tuberculosis. It is administered with other antituberculous drugs usually including rifampicin and pyrazinamide. Prophylaxis of tuberculosis in high risk subjects. Isoniazid is given in the initial and continuation phase of short-course tuberculosis regimens.
Dosage/Direction for Use
Adults: Usual Dose: 300 mg daily orally on an empty stomach.
Children: 5 mg/kg body weight daily. Maximum Dose: 300 mg daily.
Intermittent Therapy: 10 mg/kg body weight 3 times weekly or 15 mg/kg body weight twice weekly. Maximum Dose: 900 mg.
Doses may need to be reduced in patients with hepatic impairment or moderate to severe renal impairment.
Tuberculosis Prophylaxis: Daily dose of 300 mg are given for at least 6 months and sometimes for up to 1 year.
Children: 5 mg/kg body weight daily. Maximum Dose: 300 mg daily.
Intermittent Therapy: 10 mg/kg body weight 3 times weekly or 15 mg/kg body weight twice weekly. Maximum Dose: 900 mg.
Doses may need to be reduced in patients with hepatic impairment or moderate to severe renal impairment.
Tuberculosis Prophylaxis: Daily dose of 300 mg are given for at least 6 months and sometimes for up to 1 year.
Special Precautions
Isoniazid should be administered with caution to patients with convulsive disorders, a history of psychosis or hepatic or renal dysfunction. Patients who are at risk of neuropathy or pyridoxine deficiency, including those who are diabetic, alcoholic, malnourished, uremic, pregnant or HIV-infected should receive pyridoxine usually in a dose of 10 mg daily, although some have suggested using up to 50 mg daily. If symptoms of hepatitis eg, malaise, fatigue, anorexia and nausea develop, isoniazid should be discontinued pending evaluation.
Liver function should be checked before treatment with isoniazid and special care should be taken in alcoholic patients or those with preexisting liver disease.
Liver function should be checked before treatment with isoniazid and special care should be taken in alcoholic patients or those with preexisting liver disease.
Adverse Reactions
Isoniazid is generally well-tolerated at currently recommended doses. However, patients who are slow acetylators of isoniazid appear to have a higher incidence of some adverse effects. Also, patients whose nutrition is poor are at risk of peripheral neuritis which is one of the most common adverse effect of isoniazid. Other neurological adverse effects include psychotic reactions and convulsions. Pyridoxine may be given to prevent or treat these adverse effects. Optic neuritis has also been reported.
Hematological effects reported following use of isoniazid include various anemias, agranulocytosis, thrombocytopenia and eosinophilia.
Other adverse effects include nausea, vomiting, pellagra, purpura, hyperglycemia, lupus-like syndrome, urinary retention and gynecomastia.
Treatment of Adverse Effects: Pyridoxine HCl 10 mg daily has been recommended to prophylaxis of peripheral neuritis associated with isoniazid although some have suggested using up to 50 mg daily.
Hematological effects reported following use of isoniazid include various anemias, agranulocytosis, thrombocytopenia and eosinophilia.
Other adverse effects include nausea, vomiting, pellagra, purpura, hyperglycemia, lupus-like syndrome, urinary retention and gynecomastia.
Treatment of Adverse Effects: Pyridoxine HCl 10 mg daily has been recommended to prophylaxis of peripheral neuritis associated with isoniazid although some have suggested using up to 50 mg daily.
Storage
Store at temperatures not exceeding 30°C.
Action
Microbiology: Isoniazid is highly active against Mycobacterium tuberculosis which it inhibits in vitro at concentrations of 0.02-0.2 mcg/mL. Isoniazid may have activity against some strains of the mycobacteria including M. kansasii.
Although it is rapidly bactericidal against actively dividing M. tuberculosis, it is considered to be only bacteriostatic against semi-dormant organisms and has less sterilizing activity than rifampicin or pyrazinamide. Pharmacokinetics: Peak concentrations of about 3-8 mcg/mL appear in blood 1-2 hrs after a fasting dose of 300 mg orally. The rate and extent of absorption of isoniazid is reduced by food. Isoniazid s not considered to be bound appreciably to plasma proteins and diffuses into all body tissues and fluids, including breast milk.
The plasma t½ for isoniazid ranges from about 1-6 hrs, those who are fast acetylators having shorter t½. The primary metabolic route is the acetylation of isoniazid to acetylisoniazid by N-acetyltransferase found in the liver and small intestines. Acetylisoniazid is then hydrolyzed to isonicotinic acid and monoacetylhydrazine; isonicotinic acid is conjugated with glycine to isonicotinyl glycine (isonicotinuric acid) and monoacetylhydrazine is further acetylated to diacetylhydrazine. Some unmetabolized isoniazid is conjugated to hydrazones. The metabolites of isoniazid have no tuberculostatic activity and apart from possibly monoacetylhydrazine, they are also less toxic.
In patients with normal renal function, over 75% of a dose appears in the urine in 24 hrs mainly as metabolites. Small amounts of drug are also excreted in the feces. Isoniazid is removed by dialysis.
Although it is rapidly bactericidal against actively dividing M. tuberculosis, it is considered to be only bacteriostatic against semi-dormant organisms and has less sterilizing activity than rifampicin or pyrazinamide. Pharmacokinetics: Peak concentrations of about 3-8 mcg/mL appear in blood 1-2 hrs after a fasting dose of 300 mg orally. The rate and extent of absorption of isoniazid is reduced by food. Isoniazid s not considered to be bound appreciably to plasma proteins and diffuses into all body tissues and fluids, including breast milk.
The plasma t½ for isoniazid ranges from about 1-6 hrs, those who are fast acetylators having shorter t½. The primary metabolic route is the acetylation of isoniazid to acetylisoniazid by N-acetyltransferase found in the liver and small intestines. Acetylisoniazid is then hydrolyzed to isonicotinic acid and monoacetylhydrazine; isonicotinic acid is conjugated with glycine to isonicotinyl glycine (isonicotinuric acid) and monoacetylhydrazine is further acetylated to diacetylhydrazine. Some unmetabolized isoniazid is conjugated to hydrazones. The metabolites of isoniazid have no tuberculostatic activity and apart from possibly monoacetylhydrazine, they are also less toxic.
In patients with normal renal function, over 75% of a dose appears in the urine in 24 hrs mainly as metabolites. Small amounts of drug are also excreted in the feces. Isoniazid is removed by dialysis.
MedsGo Class
Anti-TB Agents
Please sign in so that we can notify you about a reply